AMRC Response: OSTP Request for Information – Accelerating the American Scientific Enterprise
The Association of Multisite Research Corporations (AMRC) appreciates the opportunity to comment on this important Federal policy update on accelerating the American scientific enterprise. AMRC applauds any initiative to advance science and clinical trials to the benefit of patients.
Collaboration over competition: Rovia’s CEO on the future of clinical research
Patricio brings over 20 years of leadership experience in healthcare across various sectors including pharma, med device, value-based primary care, hospital, pharmacy, and DME. He earned a B.S. in Biology from Duke University and an M.B.A from Stanford University. He’s an alum of Eli Lilly, and Johnson & Johnson, where his passion for medical innovation first took root.
At the helm of AMR Clinical: Kari Delahunty’s vision for patient-first research
It was the photos that caught her eye. Vibrant images of patients, both adults and children, lining the walls of the interview room. For Kari Delahunty, those faces represented more than statistics, they were stories of lives changed through clinical trials.
The Network Advantage: defining and recognizing quality in clinical research
Join us as we present the findings of AMRC’s 2025 industry consultation on quality in clinical research and outline the steps the association will take to define and recognise quality in practice.
From expansion to infrastructure: what Tekton Research’s growth signals for MCRCs
Tekton Research’s recent announcement of two new research sites in New Carlisle, Ohio, and Englewood, New Jersey, reflects more than geographic growth. It offers a clear view into how multisite clinical research corporations (MCRCs) are evolving from collections of sites into scalable research infrastructure designed for speed, quality, and access.
AMRC welcomes three new members
The Association of Multisite Research Corporations (AMRC) today announced the addition of three new members,Rovia Clinical Research, K2 Medical Research, and Eximia, further expanding its representation of leading multisite research organizations across the United States and internationally.
Clinical Trials Sector Braces for Wave of M&A
When Headlands Research was acquired by THL Partners earlier this year, the deal sent a clear signal: consolidation in the clinical trials sector is accelerating. Investors are taking a hard look at the potential of site networks and multisite clinical research corporations (MCRCs) to deliver the scale, quality, and efficiency demanded by sponsors, CROs, and patients.
From headwinds to tailwinds: what can we expect for the rest of 2025 in clinical trials?
There’s an ancient Chinese expression that says, “may you live in interesting times.” For the clinical trial industry, the word “interesting” doesn’t even begin to cover the roller-coaster ride of regulatory changes, disappearing grants, and general uncertainty it’s endured over the past six to twelve months.
Member Spotlight: Headlands to be Acquired by THL Partners, Signalling Growing Investor Confidence in the MCRC Model
AMRC founding member Headlands Research has announced its pending acquisition by THL Partners, marking an important moment for both the organization and the broader clinical trials sector. The deal reflects the rapidly rising interest of the investment community in the future of multisite clinical research corporations (MCRCs).
Federal News Update: NIH Funding, Vaccine Policy and Looming Drug Pricing Deadline
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
